BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16272364)

  • 1. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.
    Bill JR; Mack DG; Falta MT; Maier LA; Sullivan AK; Joslin FG; Martin AK; Freed BM; Kotzin BL; Fontenot AP
    J Immunol; 2005 Nov; 175(10):7029-37. PubMed ID: 16272364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
    Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
    Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease.
    Lombardi G; Germain C; Uren J; Fiorillo MT; du Bois RM; Jones-Williams W; Saltini C; Sorrentino R; Lechler R
    J Immunol; 2001 Mar; 166(5):3549-55. PubMed ID: 11207315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.
    Fontenot AP; Keizer TS; McCleskey M; Mack DG; Meza-Romero R; Huan J; Edwards DM; Chou YK; Vandenbark AA; Scott B; Burrows GG
    J Immunol; 2006 Sep; 177(6):3874-83. PubMed ID: 16951350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity.
    Rogliani P; Amicosante M; Berretta F; Dotti C; Bocchino M; O'Donnell KM; Saltini C
    Int J Immunopathol Pharmacol; 2004; 17(2 Suppl):3-10. PubMed ID: 15345185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.
    Maier LA; McGrath DS; Sato H; Lympany P; Welsh K; Du Bois R; Silveira L; Fontenot AP; Sawyer RT; Wilcox E; Newman LS
    J Immunol; 2003 Dec; 171(12):6910-8. PubMed ID: 14662898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell recognition in chronic beryllium disease.
    Amicosante M; Fontenot AP
    Clin Immunol; 2006 Nov; 121(2):134-43. PubMed ID: 16697706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
    Richeldi L; Sorrentino R; Saltini C
    Science; 1993 Oct; 262(5131):242-4. PubMed ID: 8105536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP.
    Fontenot AP; Newman LS; Kotzin BL
    Clin Immunol; 2001 Jul; 100(1):4-14. PubMed ID: 11414740
    [No Abstract]   [Full Text] [Related]  

  • 10. Linking genetic susceptibility and T cell activation in beryllium-induced disease.
    Falta MT; Bowerman NA; Dai S; Kappler JW; Fontenot AP
    Proc Am Thorac Soc; 2010 May; 7(2):126-9. PubMed ID: 20427584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles.
    Wang Z; White PS; Petrovic M; Tatum OL; Newman LS; Maier LA; Marrone BL
    J Immunol; 1999 Aug; 163(3):1647-53. PubMed ID: 10415070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.
    Amicosante M; Berretta F; Franchi A; Rogliani P; Dotti C; Losi M; Dweik R; Saltini C
    Eur Respir J; 2002 Nov; 20(5):1174-8. PubMed ID: 12449171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69.
    Amicosante M; Sanarico N; Berretta F; Arroyo J; Lombardi G; Lechler R; Colizzi V; Saltini C
    Hum Immunol; 2001 Jul; 62(7):686-93. PubMed ID: 11423174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beryllium sensitivity is linked to HLA-DP genotype.
    Wang Z; Farris GM; Newman LS; Shou Y; Maier LA; Smith HN; Marrone BL
    Toxicology; 2001 Aug; 165(1):27-38. PubMed ID: 11551429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease.
    Fontenot AP; Maier LA
    Trends Immunol; 2005 Oct; 26(10):543-9. PubMed ID: 16099719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease.
    Mack DG; Falta MT; McKee AS; Martin AK; Simonian PL; Crawford F; Gordon T; Mercer RR; Hoover MD; Marrack P; Kappler JW; Tuder RM; Fontenot AP
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8553-8. PubMed ID: 24912188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease.
    Falta MT; Pinilla C; Mack DG; Tinega AN; Crawford F; Giulianotti M; Santos R; Clayton GM; Wang Y; Zhang X; Maier LA; Marrack P; Kappler JW; Fontenot AP
    J Exp Med; 2013 Jul; 210(7):1403-18. PubMed ID: 23797096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell recognition of beryllium.
    Dai S; Falta MT; Bowerman NA; McKee AS; Fontenot AP
    Curr Opin Immunol; 2013 Dec; 25(6):775-80. PubMed ID: 23978481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice.
    Falta MT; Tinega AN; Mack DG; Bowerman NA; Crawford F; Kappler JW; Pinilla C; Fontenot AP
    Mucosal Immunol; 2016 Jan; 9(1):218-28. PubMed ID: 26129650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease.
    Gaede KI; Amicosante M; Schürmann M; Fireman E; Saltini C; Müller-Quernheim J
    J Mol Med (Berl); 2005 May; 83(5):397-405. PubMed ID: 15750822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.